Your Feed

Filter by
See content from
Back to the latest
Avatar
rubyCrocodile
Multiple Myeloma Discussion • January 1
M Spike and light chains after CarT treatment
Question for people who had CarT treatment: What was your free light chains and M spike around 100 days after the treatment?
Avatar
JaneF
Multiple Myeloma Discussion • January 1
CAR-T
What is it like going through CAR-T? What advice would you give a person to make it go smoother?
Avatar
JimLuby
Multiple Myeloma Discussion • December 31
Darzalex faspro pharmacy charges
The pharmacy is charging $51,000 for one 1800 ml injection plus the hospital fees. What are you seeing as pharmacy charges for faspro?
Avatar
DIahanna • Admin
Multiple Myeloma Discussion • December 30
Higher premiums for ACA plans
For those of you who have taken advantage of the subsidies for ACA premiums, you may see a significant increase in your premium which you will be responsible for. Make sure you are taking advantage of grants that may be available to you to help offset the costs of your tratment. Reach out to a financial coach to discuss your options.
Avatar
CHidalgo
Multiple Myeloma Discussion • December 29
Neuropathy and Maintance
Hello! I have 2 issues I would love your advice with: 1. I am about 2 months post SCT. I think I just developed neuropathy on both my hands but not sure since I have never had it before. Is it normal to develop neoropathy 2 months after SCT? I did not experience this during my induction treatment. What exactly does neuropathy feel like for you guys? What has worked for you to relieve symptoms? 2. I am about to start maintance drugs. Doctor suggested Velcade. But with my neoropathy I am not sure. Worried it will make it worse, I did not experience this while on velcade during my induction treatment. Has anyone been on this for maintance and how did it work for you? Other option is Lenalidmide. I am concerned with the possible sife effect of other cancers....I was also already on this with no major issues just worried since I will be on it for a long period. Thank you for taking the time to read my concerns!
Avatar
XimenaG • Admin
Multiple Myeloma Discussion • December 29
A Heartfelt Thank You to Our Community
As we close our 'Why I Give' campaign, we would like to thank every patient, caregiver, supporter, volunteer, and team member who shared their reason. Your voices filled this season with hope. At HealthTree, YOU are the heart of our mission. Your courage, your stories, and your willingness to stand with us are what move research forward and bring us closer to cures every day. Thank you for showing up. Thank you for believing in what’s possible. #WhyIGive #WeCareWeCure #HealthTreeGives #BloodCancerCommunity #TogetherForACure
Thumbnail for Less Invasive AML & MDS Monitoring: Blood Tests & Machine Learning | Lisa Pleyer, MD
Playlist: ASH 2025

Less Invasive AML & MDS Monitoring: Blood Tests & Machine Learning | Lisa Pleyer, MD

Video details & playlist
Avatar
selenasuarez
Multiple Myeloma Discussion • December 26
Caregiver Working During SCT?
Hi everyone — I hope you had a great holiday. My mom is preparing for a stem cell transplant at the end of January, and my dad has received an in-person job offer starting around that time. As we plan for caregiving, we’d appreciate guidance to help us decide whether he should accept the role. After the transplant, what level of at-home support is typically needed, and for how long? Is 24/7 care required, or could she be alone during the day if my dad worked an in-person 8–5 job? From an infection-risk standpoint, is it generally safe for the primary caregiver to work outside the home and return daily? How do families usually manage work and caregiving during recovery?
Thumbnail for Real‑World Results for Menin Inhibitors in Hard‑to‑Treat AML | Kuo-Kai Chin, MD
Playlist: ASH 2025

Real‑World Results for Menin Inhibitors in Hard‑to‑Treat AML | Kuo-Kai Chin, MD

Video details & playlist
Dear fellow caregivers and MM sufferers, I have been using ChatGPT to help me understand blood work and bone marrow results for the last year of treatment, which began with my wife's kidney failure in January of 2025 and the subsequent diagnose of MM. Her recovery has been spectacular with minimal side effects. With help from Chat, I have composed the following letter (a bit long perhaps) in preparation for our January 6th oncologist appointment. Please comment as you see fit, particularly as to whether or not I am being reasonable. Current Therapy (as of Dec 2025) • Anti-CD38 monoclonal antibody infusion every 2 weeks • Lenalidomide 25 mg, days 1–21 of 28-day cycle • Corticosteroids: weekly oral dexamethasone plus IV methylprednisolone with infusions • Zoledronic acid monthly • IVIG monthly for hypogammaglobulinemia ________________________________________ Objective Evidence of Disease Control Bone Marrow • No detectable malignant plasma cells • Hematopoiesis recovered CBC Trends (Jan–Dec 2025) • Early severe cytopenias resolved • Sustained hemoglobin ~13–15 g/dL • WBC stable • Platelets fluctuating but largely safe (120–220k) • Persistent macrocytosis consistent with treatment effect SPEP / Immunoglobulins • No rising monoclonal spike • Persistent hypogammaglobulinemia (gamma globulin ~0.5 g/dL) • Pattern consistent with treatment-related immune suppression, not progression Ferritin • Elevated but declining over time • Consistent with inflammation/transfusion/steroid exposure rather than disease activity ________________________________________ Clinical Interpretation • Current laboratory abnormalities are more consistent with cumulative treatment toxicity than active myeloma • Patient appears to be in a deep, durable response approaching functional remission • Ongoing full-intensity therapy may be contributing to: o Immune suppression requiring IVIG o Cytopenias and macrocytosis o Steroid-related adverse effects ________________________________________ Proposed Stepwise De-escalation (Risk-Minimizing) 1. Steroids (highest priority) • Reduce weekly dexamethasone dose by ≥50% or discontinue oral weekly dosing • Rationale: minimal added disease control in deep responders, high toxicity burden 2. Lenalidomide optimization • Reduce dose (e.g., 10–15 mg) • Or modify schedule (e.g., 14 days on / 14 days off) • Rationale: marrow stress, cytopenias, immune suppression 3. Infusion spacing • Consider extending monoclonal antibody infusions to every 4 weeks • Alternatively, trial close-monitoring pause 4. Bone agent reassessment • Consider spacing zoledronic acid to every 3 months or discontinuation if no active bone disease 5. IVIG reassessment • Goal: reduce need by allowing immune reconstitution following therapy de-escalation ________________________________________ Monitoring Plan to Mitigate Risk • Monthly CBC, SPEP, free light chains • Symptom surveillance • Rapid re-escalation if biochemical or clinical relapse detected ________________________________________ Key Question for Discussion Can we preserve disease control while reducing treatment-related toxicity and improving immune recovery through a cautious, stepwise de-escalation strategy?
Avatar
Iliana • Admin
Acute Myeloid Leukemia Discussion • December 24
Sending Holiday Wishes and Gratitude
AI-generated title
From everyone at HealthTree, we extend our warm wishes for a peaceful holiday season, surrounded by those who support and care for you. ❤️ We are sincerely grateful to every patient, caregiver, loved one, specialist, and collaborator whose voice and presence shaped our community this year. Your experiences, trust, and engagement help guide our work and strengthen efforts to improve the quality of life and access to better treatments for all patients. Thank you for being part of HealthTree and for allowing us to support you on your journey. With appreciation, The HealthTree Team
Avatar
Iliana • Admin
Multiple Myeloma Discussion • December 24
Our Holiday Gratitude for This Community
AI-generated title
From everyone at HealthTree, we extend our warm wishes for a peaceful holiday season, surrounded by those who support and care for you. ❤️ We are sincerely grateful to every patient, caregiver, loved one, specialist, and collaborator whose voice and presence shaped our community this year. Your experiences, trust, and engagement help guide our work and strengthen efforts to improve the quality of life and access to better treatments for all patients. Thank you for being part of HealthTree and for allowing us to support you on your journey. With appreciation, The HealthTree Team
Avatar
3sisterskaye
Multiple Myeloma Discussion • December 23
Light chains went up after
I’ve been on Talvey for about two months. Worked great This blood test showed light chains went up to 33. I know that’s low but was worried the mm was starting to come back already. Was wondering if this has happened to anyone or just adjusting? I have a call into my doctor but thought this would be quicker. Thank you.
Thumbnail for Remote Patient Monitoring for Outpatient Bispecific Therapy in Myeloma | Sridevi Rajeeve, MD
Playlist: ASH 2025

Remote Patient Monitoring for Outpatient Bispecific Therapy in Myeloma | Sridevi Rajeeve, MD

Video details & playlist
Thumbnail for Arlo-Cel - GPRC5D CAR-T: High Response Rates in Heavily Pretreated Myeloma | Susan Bal, MD
Playlist: ASH 2025

Arlo-Cel - GPRC5D CAR-T: High Response Rates in Heavily Pretreated Myeloma | Susan Bal, MD

Video details & playlist